Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
Identifieur interne : 003244 ( Main/Exploration ); précédent : 003243; suivant : 003245Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
Auteurs : RBID : pubmed:14506196English descriptors
- KwdEn :
- Adult, Aged, Antibodies, Bispecific (chemistry), Antibodies, Bispecific (pharmacokinetics), Bone Marrow (pathology), Carcinoembryonic Antigen (chemistry), Female, Haptens (chemistry), Humans, Iodine Radioisotopes (therapeutic use), Male, Middle Aged, Neoplasm Metastasis, Neoplasms (therapy), Quality Control, Radioimmunotherapy (methods), Radiometry, Time Factors, Tissue Distribution.
- MESH :
- chemical , chemistry : Antibodies, Bispecific, Carcinoembryonic Antigen, Haptens.
- chemical , pharmacokinetics : Antibodies, Bispecific.
- methods : Radioimmunotherapy.
- pathology : Bone Marrow.
- chemical , therapeutic use : Iodine Radioisotopes.
- therapy : Neoplasms.
- Adult, Aged, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Quality Control, Radiometry, Time Factors, Tissue Distribution.
Abstract
Pharmacokinetics and dosimetry of hMN-14 x m734 bispecific monoclonal antibody (BsMAb) and (131)I-labeled di-diethylenetriaminepentaacetic acid-indium ((131)I-hapten) were studied to optimize pretargeted radioimmunotherapy.
PubMed: 14506196
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.</title><author><name sortKey="Kraeber Bodere, Francoise" uniqKey="Kraeber Bodere F">Françoise Kraeber-Bodéré</name><affiliation wicri:level="3"><nlm:affiliation>Nuclear Medicine Department, René Gauducheau Cancer Center, 44805 Saint Herblain, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Nuclear Medicine Department, René Gauducheau Cancer Center, 44805 Saint Herblain</wicri:regionArea><placeName><region type="region" nuts="2">Pays de la Loire</region><settlement type="city">Saint Herblain</settlement></placeName></affiliation></author><author><name sortKey="Faivre Chauvet, Alain" uniqKey="Faivre Chauvet A">Alain Faivre-Chauvet</name></author><author><name sortKey="Ferrer, Ludovic" uniqKey="Ferrer L">Ludovic Ferrer</name></author><author><name sortKey="Vuillez, Jean Philippe" uniqKey="Vuillez J">Jean-Philippe Vuillez</name></author><author><name sortKey="Brard, Pierre Yves" uniqKey="Brard P">Pierre-Yves Brard</name></author><author><name sortKey="Rousseau, Caroline" uniqKey="Rousseau C">Caroline Rousseau</name></author><author><name sortKey="Resche, Isabelle" uniqKey="Resche I">Isabelle Resche</name></author><author><name sortKey="Devillers, Anne" uniqKey="Devillers A">Anne Devillers</name></author><author><name sortKey="Laffont, Sophie" uniqKey="Laffont S">Sophie Laffont</name></author><author><name sortKey="Bardies, Manuel" uniqKey="Bardies M">Manuel Bardiès</name></author><author><name sortKey="Chang, Ken" uniqKey="Chang K">Ken Chang</name></author><author><name sortKey="Sharkey, Robert M" uniqKey="Sharkey R">Robert M Sharkey</name></author><author><name sortKey="Goldenberg, David M" uniqKey="Goldenberg D">David M Goldenberg</name></author><author><name sortKey="Chatal, Jean Francois" uniqKey="Chatal J">Jean-François Chatal</name></author><author><name sortKey="Barbet, Jacques" uniqKey="Barbet J">Jacques Barbet</name></author></titleStmt><publicationStmt><date when="2003">2003</date><idno type="RBID">pubmed:14506196</idno><idno type="pmid">14506196</idno><idno type="wicri:Area/Main/Corpus">003388</idno><idno type="wicri:Area/Main/Curation">003388</idno><idno type="wicri:Area/Main/Exploration">003244</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antibodies, Bispecific (chemistry)</term><term>Antibodies, Bispecific (pharmacokinetics)</term><term>Bone Marrow (pathology)</term><term>Carcinoembryonic Antigen (chemistry)</term><term>Female</term><term>Haptens (chemistry)</term><term>Humans</term><term>Iodine Radioisotopes (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Neoplasms (therapy)</term><term>Quality Control</term><term>Radioimmunotherapy (methods)</term><term>Radiometry</term><term>Time Factors</term><term>Tissue Distribution</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antibodies, Bispecific</term><term>Carcinoembryonic Antigen</term><term>Haptens</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antibodies, Bispecific</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radioimmunotherapy</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Bone Marrow</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Iodine Radioisotopes</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Quality Control</term><term>Radiometry</term><term>Time Factors</term><term>Tissue Distribution</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pharmacokinetics and dosimetry of hMN-14 x m734 bispecific monoclonal antibody (BsMAb) and (131)I-labeled di-diethylenetriaminepentaacetic acid-indium ((131)I-hapten) were studied to optimize pretargeted radioimmunotherapy.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">14506196</PMID><DateCreated><Year>2003</Year><Month>09</Month><Day>24</Day></DateCreated><DateCompleted><Year>2004</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1078-0432</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>10 Pt 2</Issue><PubDate><Year>2003</Year><Month>Sep</Month><Day>1</Day></PubDate></JournalIssue><Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title><ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation></Journal><ArticleTitle>Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.</ArticleTitle><Pagination><MedlinePgn>3973S-81S</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Pharmacokinetics and dosimetry of hMN-14 x m734 bispecific monoclonal antibody (BsMAb) and (131)I-labeled di-diethylenetriaminepentaacetic acid-indium ((131)I-hapten) were studied to optimize pretargeted radioimmunotherapy.</AbstractText><AbstractText Label="EXPERIMENTAL DESIGN" NlmCategory="METHODS">Thirty-five patients with carcinoembryonic antigen-expressing tumors were included. In a first group of 12 patients, (131)I-trace-labeled BsMAb doses were escalated from 10 to 100 mg/m(2), and 3.7 GBq of (131)I-hapten were administered 7 days later. In a second group, 12 patients received 75 mg/m(2) BsMAb and 2.6-4.2 GBq of (131)I-hapten 5 days later. The BsMAb dose was then reduced to 40 mg/m(2), and 10 patients received 1.9-5.5 GBq of (131)I-hapten. Blood samples were collected. Biodistribution was monitored by quantitative scintigraphy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Directly labeled BsMAb pharmacokinetics was described by two exponentials: half-lives were 8.1 h (2.0-18.1 h) and 48.2 h (22.8-79.4 h); blood clearance was 123 ml/h (64-195 ml/h). With a 7-day interval, 10 or 30 mg/m(2) BsMAb resulted in fast elimination and very low tumor uptake of hapten, whereas 50 or 100 mg/m(2) resulted in favorable tumor accretion. With 75 mg/m(2) BsMAb and a 5-day interval, hapten clearance was 152 ml/h (81-298 ml/h). Calculated radiation dose to tumor was 3.9 Gy/GBq (0.4-22.4 Gy/GBq) for the hapten, compared with 2.0 Gy/GBq (0.3-3.8 Gy/GBq) for the BsMAb, but hematological toxicity prevented dose escalation. Reduction of the BsMAb dose to 40 mg/m(2) accelerated hapten clearance to 492 ml/h (113-2544 ml/h) and reduced hematological toxicity without compromising tumor uptake [5.2 Gy/GBq (0.5-12.6 Gy/GBq)].</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Optimized BsMAb doses and time interval will allow for the administration of higher, tumoricidal, activity doses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kraeber-Bodéré</LastName><ForeName>Françoise</ForeName><Initials>F</Initials><Affiliation>Nuclear Medicine Department, René Gauducheau Cancer Center, 44805 Saint Herblain, France.</Affiliation></Author><Author ValidYN="Y"><LastName>Faivre-Chauvet</LastName><ForeName>Alain</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ferrer</LastName><ForeName>Ludovic</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Vuillez</LastName><ForeName>Jean-Philippe</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Brard</LastName><ForeName>Pierre-Yves</ForeName><Initials>PY</Initials></Author><Author ValidYN="Y"><LastName>Rousseau</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Resche</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Devillers</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Laffont</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bardiès</LastName><ForeName>Manuel</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Sharkey</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Goldenberg</LastName><ForeName>David M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>Chatal</LastName><ForeName>Jean-François</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Barbet</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Clinical Trial</PublicationType><PublicationType>Clinical Trial, Phase I</PublicationType><PublicationType>Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Cancer Res</MedlineTA><NlmUniqueID>9502500</NlmUniqueID><ISSNLinking>1078-0432</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Bispecific</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Carcinoembryonic Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Haptens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Iodine Radioisotopes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Bispecific</DescriptorName><QualifierName MajorTopicYN="Y">chemistry</QualifierName><QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Bone Marrow</DescriptorName><QualifierName MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoembryonic Antigen</DescriptorName><QualifierName MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Haptens</DescriptorName><QualifierName MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Iodine Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Quality Control</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radioimmunotherapy</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>9</Month><Day>25</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>9</Month><Day>25</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14506196</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003244 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003244 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:14506196
|texte= Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:14506196" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |